Silverarc Capital Management, LLC Terns Pharmaceuticals, Inc. Transaction History

Silverarc Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$4.86 - $8.19 $1.29 Million - $2.18 Million	-266,448 Reduced 51.54%	250,551 $1.64 Million
Q4 2023 Feb 14, 2024	BUY	$3.37 - $6.86 $57,286 - $116,613	16,999 Added 3.4%	516,999 $3.36 Million
Q3 2023 Nov 13, 2023	SELL	$4.7 - $8.55 $468,439 - $852,161	-99,668 Reduced 16.62%	500,000 $2.52 Million
Q2 2023 Aug 14, 2023	SELL	$7.35 - $13.29 $501,666 - $907,095	-68,254 Reduced 10.22%	599,668 $5.25 Million
Q1 2023 May 15, 2023	SELL	$7.91 - $12.0 $253,736 - $384,936	-32,078 Reduced 4.58%	667,922 $7.91 Million
Q4 2022 Feb 14, 2023	BUY	$4.62 - $10.18 $3.17 Million - $6.98 Million	685,527 Added 4736.59%	700,000 $7.13 Million
Q3 2022 Oct 28, 2022	BUY	$1.87 - $6.42 $27,064 - $92,916	14,473 New	14,473 $85,000

167

78.3M

580K

454K

Ticker TERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,613,800
Market Cap $224M
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.